Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT02365246

Treatment of AD With IgE Specific Immunoadsorption (IGEIAAD)

Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2024-07-15

15

Participants Needed

1

Research Sites

591 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Removal of IgE through adsorption of IgE on a specially designed column after apheresis of blood has the potential to improve the severity of atopic dermatitis. In this study the investigators will treat patients with a severe form of Atopic dermatitis not responding or having to much side effects to systemic imunosuppressive treatment with this modality.

CONDITIONS

Official Title

Treatment of AD With IgE Specific Immunoadsorption (IGEIAAD)

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults older than 18 years with severe atopic dermatitis (objective SCORAD greater than 40)
  • Atopic dermatitis that has been persistent and stable for more than 1 year
  • Signed informed consent to participate
  • Not pregnant and not planning pregnancy during immunoadsorption treatment
  • Previously treated with phototherapy or immunosuppressive therapies (such as cyclosporin A, methotrexate, azathioprine, mycophenolate, systemic corticosteroids) that were ineffective, caused unacceptable side effects, or were contraindicated
Not Eligible

You will not qualify if you...

  • Did not give informed consent
  • Have mild or moderate atopic dermatitis
  • Have severe atopic dermatitis that improves with and tolerates standard therapies without contraindications
  • Pregnant women or women planning pregnancy during or immediately after treatment
  • Contraindications to immunoadsorption including allergy to treatment materials, severe cardiovascular disease, severe bleeding during anticoagulation, treatment with ACE inhibitors, or being under 18 years old
  • Having an active malignant disease not in remission

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UZ Leuven

Leuven, Belgium, 3000

Actively Recruiting

Loading map...

Research Team

M

Marie-Anne C Morren, MD

CONTACT

B

Björn Meijers, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Treatment of AD With IgE Specific Immunoadsorption (IGEIAAD) | DecenTrialz